Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Peripheral Nervous System Diseases 1Colorectal Neoplasms 1Cognitive Dysfunction 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Trastuzumab 2Ivabradine 2Exercise 2Echocardiography 2Bisoprolol 2salicylhydroxamic acid 1sacubitril and valsartan sodium hydrate drug combination 1mitoquinone 1epicatechin gallate 1dapagliflozin 1candesartan 1Trimetazidine 1Therapeutics 1Surveys and Questionnaires 1Spironolactone 1Silymarin 1Secondary Prevention 1Restraint, Physical 1Ramipril 1Radiotherapy 1Perindopril 1Neoadjuvant Therapy 1Nebivolol 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Fluorouracil 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Cisplatin 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Cardiotoxicity × Silymarin × Clear all
NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown
56 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡